Blue Cross Blue Shield · Zepbound and Wegovy coverage

Does Blue Cross Blue Shield cover Zepbound or Wegovy?

Last updated

It depends on your Blue company and plan; several ended weight-loss coverage.

If it is not covered: the lowest cash prices now

  • Without insurance: compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Without insurance: compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

It depends on your Blue company and plan; several ended weight-loss coverage. Blue Cross Blue Shield of Massachusetts ended coverage of GLP-1s for weight loss at each plan's renewal from January 1, 2026, keeping coverage for type 2 diabetes. In its words: "We’ve made the decision to end coverage for GLP-1 medications, except for type 2 diabetes. This change will take effect upon your plan renewal, starting January 1, 2026." (Blue Cross Blue Shield of Massachusetts member page, We've changed our GLP-1 coverage, bluecrossma.org/glp-1-coverage-update, Jan 1, 2026, read Nov 17, 2026). At Blue Cross Blue Shield of Massachusetts only employers with more than 100 employees can keep Wegovy and Zepbound coverage; smaller groups and direct-pay members lost it at renewal, and the exclusion cannot be appealed. In its words: "If your company has more than 100 employees, your employer will have the option to continue coverage. If they choose not to, upon plan renewal starting January 1, 2026, Wegovy, Saxenda, and Zepbound will no longer be covered, even if you’re currently using them." (Blue Cross Blue Shield of Massachusetts member page, We've changed our GLP-1 coverage, bluecrossma.org/glp-1-coverage-update, Jan 1, 2026, read Nov 17, 2026). Blue Cross Blue Shield of Michigan and Blue Care Network ended weight-loss GLP-1 coverage for fully insured large group commercial members from January 1, 2025 (or the group's renewal date); self-funded groups could keep covering them. In its words: "Coverage for GLP-1 weight loss drugs for fully-insured large group commercial members will end starting Jan. 1, 2025. For group members with a plan renewal date other than Jan. 1, the coverage will end on the renewal date." (Blue Cross Blue Shield of Michigan and BCN provider alert, Changes coming for select weight loss drugs for some commercial members, posted June 6, 2024, updated July 30, 2024, providerinfo.bcbsm.com, read Nov 17, 2026). Blue Cross and Blue Shield of Vermont made Wegovy, Zepbound and Saxenda for weight loss a benefit exclusion from January 1, 2026, but keeps covering Wegovy with prior approval for adults with cardiovascular disease and obesity. In its words: "Beginning January 1, 2026, Blue Cross and Blue Shield of Vermont will no longer cover prescription drugs containing Glucagon-Like Peptide-1 (GLP-1) receptor agonists that are FDA-approved for weight loss, including Wegovy®, Zepbound® and Saxenda®. This will be a benefit exclusion." (Blue Cross and Blue Shield of Vermont, Frequently Asked Questions: 2026 Coverage Changes for GLP-1 Drugs FDA-Approved for Weight Loss, bluecrossvt.org/documents/glp-1-faqs, read Nov 17, 2026).

Company by company

Each Blue Cross Blue Shield company's own rule

Questions

Blue Cross Blue Shield, Zepbound and Wegovy: common questions

Does Blue Cross Blue Shield cover Zepbound for weight loss?

It depends on your Blue company and plan; several ended weight-loss coverage. Blue Cross Blue Shield of Massachusetts ended coverage of GLP-1s for weight loss at each plan's renewal from January 1, 2026, keeping coverage for type 2 diabetes. In its words: "We’ve made the decision to end coverage for GLP-1 medications, except for type 2 diabetes. This change will take effect upon your plan renewal, starting January 1, 2026." (Blue Cross Blue Shield of Massachusetts member page, We've changed our GLP-1 coverage, bluecrossma.org/glp-1-coverage-update, Jan 1, 2026, read Nov 17, 2026). At Blue Cross Blue Shield of Massachusetts only employers with more than 100 employees can keep Wegovy and Zepbound coverage; smaller groups and direct-pay members lost it at renewal, and the exclusion cannot be appealed. In its words: "If your company has more than 100 employees, your employer will have the option to continue coverage. If they choose not to, upon plan renewal starting January 1, 2026, Wegovy, Saxenda, and Zepbound will no longer be covered, even if you’re currently using them." (Blue Cross Blue Shield of Massachusetts member page, We've changed our GLP-1 coverage, bluecrossma.org/glp-1-coverage-update, Jan 1, 2026, read Nov 17, 2026). Blue Cross Blue Shield of Michigan and Blue Care Network ended weight-loss GLP-1 coverage for fully insured large group commercial members from January 1, 2025 (or the group's renewal date); self-funded groups could keep covering them. In its words: "Coverage for GLP-1 weight loss drugs for fully-insured large group commercial members will end starting Jan. 1, 2025. For group members with a plan renewal date other than Jan. 1, the coverage will end on the renewal date." (Blue Cross Blue Shield of Michigan and BCN provider alert, Changes coming for select weight loss drugs for some commercial members, posted June 6, 2024, updated July 30, 2024, providerinfo.bcbsm.com, read Nov 17, 2026). Blue Cross and Blue Shield of Vermont made Wegovy, Zepbound and Saxenda for weight loss a benefit exclusion from January 1, 2026, but keeps covering Wegovy with prior approval for adults with cardiovascular disease and obesity. In its words: "Beginning January 1, 2026, Blue Cross and Blue Shield of Vermont will no longer cover prescription drugs containing Glucagon-Like Peptide-1 (GLP-1) receptor agonists that are FDA-approved for weight loss, including Wegovy®, Zepbound® and Saxenda®. This will be a benefit exclusion." (Blue Cross and Blue Shield of Vermont, Frequently Asked Questions: 2026 Coverage Changes for GLP-1 Drugs FDA-Approved for Weight Loss, bluecrossvt.org/documents/glp-1-faqs, read Nov 17, 2026). Zepbound not covered: the cash price at your dose

Does Blue Cross Blue Shield cover Wegovy for weight loss?

It depends on your Blue company and plan; several ended weight-loss coverage. Blue Cross Blue Shield of Massachusetts ended coverage of GLP-1s for weight loss at each plan's renewal from January 1, 2026, keeping coverage for type 2 diabetes. In its words: "We’ve made the decision to end coverage for GLP-1 medications, except for type 2 diabetes. This change will take effect upon your plan renewal, starting January 1, 2026." (Blue Cross Blue Shield of Massachusetts member page, We've changed our GLP-1 coverage, bluecrossma.org/glp-1-coverage-update, Jan 1, 2026, read Nov 17, 2026). At Blue Cross Blue Shield of Massachusetts only employers with more than 100 employees can keep Wegovy and Zepbound coverage; smaller groups and direct-pay members lost it at renewal, and the exclusion cannot be appealed. In its words: "If your company has more than 100 employees, your employer will have the option to continue coverage. If they choose not to, upon plan renewal starting January 1, 2026, Wegovy, Saxenda, and Zepbound will no longer be covered, even if you’re currently using them." (Blue Cross Blue Shield of Massachusetts member page, We've changed our GLP-1 coverage, bluecrossma.org/glp-1-coverage-update, Jan 1, 2026, read Nov 17, 2026). Blue Cross Blue Shield of Michigan and Blue Care Network ended weight-loss GLP-1 coverage for fully insured large group commercial members from January 1, 2025 (or the group's renewal date); self-funded groups could keep covering them. In its words: "Coverage for GLP-1 weight loss drugs for fully-insured large group commercial members will end starting Jan. 1, 2025. For group members with a plan renewal date other than Jan. 1, the coverage will end on the renewal date." (Blue Cross Blue Shield of Michigan and BCN provider alert, Changes coming for select weight loss drugs for some commercial members, posted June 6, 2024, updated July 30, 2024, providerinfo.bcbsm.com, read Nov 17, 2026). Blue Cross and Blue Shield of Vermont made Wegovy, Zepbound and Saxenda for weight loss a benefit exclusion from January 1, 2026, but keeps covering Wegovy with prior approval for adults with cardiovascular disease and obesity. In its words: "Beginning January 1, 2026, Blue Cross and Blue Shield of Vermont will no longer cover prescription drugs containing Glucagon-Like Peptide-1 (GLP-1) receptor agonists that are FDA-approved for weight loss, including Wegovy®, Zepbound® and Saxenda®. This will be a benefit exclusion." (Blue Cross and Blue Shield of Vermont, Frequently Asked Questions: 2026 Coverage Changes for GLP-1 Drugs FDA-Approved for Weight Loss, bluecrossvt.org/documents/glp-1-faqs, read Nov 17, 2026). Wegovy not covered: the cash price at your dose

Does Blue Cross Blue Shield cover Wegovy for heart disease?

Blue Cross and Blue Shield of Vermont's FAQ says Wegovy stays covered with prior approval when prescribed to reduce cardiovascular risk in adults with cardiovascular disease and obesity. In its words: "You are an adult with diagnosed cardiovascular disease and obesity, and your provider prescribes Wegovy® to reduce your risk of certain cardiovascular events." (Blue Cross and Blue Shield of Vermont, Frequently Asked Questions: 2026 Coverage Changes for GLP-1 Drugs FDA-Approved for Weight Loss, bluecrossvt.org/documents/glp-1-faqs, read Nov 17, 2026).

What do Zepbound and Wegovy cost if Blue Cross Blue Shield does not cover them?

Zepbound costs $299/28 days at 2.5 mg and $449/28 days at 15 mg without insurance at Amazon Pharmacy and LillyDirect (Eli Lilly), checked Nov 11, 2026 on pharmacy.amazon.com and zepbound.lilly.com. At 15 mg, the terms: at Amazon Pharmacy, through Dec 31, 2026, with Lilly's self-pay card, whose terms on Lilly's Zepbound savings page say "Card expires and savings end on 12/31/2026" and require each refill within 45 days of the previous delivery, or Lilly's regular $699 applies; at LillyDirect (Eli Lilly), Self Pay Journey price with a refill within 45 days; otherwise $499 at 7.5 mg or $699 at 10 to 15 mg. Wegovy costs $199/28 days, through Dec 31, 2026 at 0.25 mg and $349/28 days at 2.4 mg without insurance at Amazon Pharmacy and NovoCare (Novo Nordisk), checked Nov 11, 2026 on pharmacy.amazon.com and novocare.com. Compounded, not FDA-approved: compounded tirzepatide from $69/mo + $199/yr membership at Collective (about $86 a month over a year with the membership); compounded semaglutide from $59/mo + $199/yr membership at Collective (about $76 a month over a year with the membership). Every GLP-1's cash price without insurance

Does Medicaid cover Zepbound or Wegovy?

It depends on the state: 10 state programs cover GLP-1s for weight loss, by KFF's January 2026 map and the states' own notices since. Every state's Medicaid answer

GLPcompare links out only to sellers with a referral program: if you sign up or buy through one of those links, we may earn a commission at no extra cost to you. For other sellers we show the price and the seller's address, and suggest sellers we can link to. It never changes the price you pay or the underlying data. Our default order is lowest price first, with sellers that pay us moved up, and the note under each list says which order it shows; every lowest-cost sort uses the price alone. In a price table, a partner's offer says so in its terms. The order is not a medical recommendation; a higher-placed offer is not necessarily the lowest price or the right product for you.

What a plan covers is decided by the plan and the employer or program behind it, and changes; check your own plan's drug list before you rely on this. This page reports the insurer's own published words and sellers' own prices, not insurance or medical advice. Compounded medications are not FDA-approved. GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.